Roche reports positive lung cancer data for Tecentriq/Avastin combination

Roche has announced the findings of a new clinical study that demonstrates the benefits of a new Tecentriq-based combination regimen for advanced lung cancer.

Positive pivotal data has been reported from the IMpower150 phase III study, which analysed Tecentriq and Avastin plus chemotherapy in people with previously untreated advanced non-squamous non-small cell lung cancer (NSCLC).

It was shown that the Tecentriq/Avastin combination was associated with a 38 percent improvement in progression-free survival (PFS) rates compared with those who received Avastin plus chemotherapy.

Notably, the 12-month landmark PFS rate was doubled for the new combination regimen compared to Avastin alone, while the rate of tumour shrinkage was also higher in people treated with Tecentriq and Avastin.

This marks the first phase III combination trial of a cancer immunotherapy to show improvement in PFS as an initial treatment in advanced non-squamous NSCLC.

Dr Sandra Horning, Roche's chief medical officer and head of global product development, said: "The IMpower150 study represents an important advance in lung cancer treatment, and we will submit these results to regulatory authorities around the world to potentially bring a new standard of care to people living with this disease as soon as possible."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.